المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin

المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Association

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test

المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel

المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life

المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Group

مصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test

المؤلفون: Ana Arance, Thomas F. Gajewski, Christian Caglevic, Mark M. Jones, Janet Maleski, Caroline Robert, Lev V. Demidov, Omid Hamid, Tae Min Kim, Scott J. Diede, Stéphane Dalle, Tara C. Mitchell, Matteo S. Carlino, Reinhard Dummer, Georgina V. Long, James R. Anderson, Jean-Jacques Grob, James Larkin

المساهمون: University of Zurich, Long, Georgina V

المصدر: Ann Transl Med

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Population, 610 Medicine & health, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Progression-free survival, education, Melanoma, Aged, education.field_of_study, Sulfonamides, business.industry, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Interim analysis, Progression-Free Survival, Clinical trial, Editorial Commentary, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, business

وصف الملف: 805_Long_GV._et_al._Epacadostat_plus_pembrolizumab_versus_placebo_plus_pembrolizumab_in_patients_with_unresectable_or_metastatic_melanoma_etc._Lancet_Oncol_2019.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994d50fe36f67262fd59a66df91baccbTest
https://www.zora.uzh.ch/id/eprint/172887Test/

المؤلفون: Jonathan Cebon, Neil Steven, Mark R. Middleton, Darcy A. Hille, Erika Richtig, Céleste Lebbé, Nageatte Ibrahim, Euan Walpole, Caroline Robert, Giuseppe Masucci, Wei Zhou, Wilson H. Miller, Teresa M. Petrella

المصدر: European Journal of Cancer. 86:115-124

مصطلحات موضوعية: Male, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Time Factors, Longitudinal data, Health Status, Population, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Quality of life, Internal medicine, medicine, Humans, In patient, Patient Reported Outcome Measures, 030212 general & internal medicine, education, Melanoma, Advanced melanoma, education.field_of_study, business.industry, Eortc qlq c30, Middle Aged, humanities, Surgery, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Quality of Life, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e890ea1bf10f65d9c5dbe680fbd78ba4Test
https://doi.org/10.1016/j.ejca.2017.08.032Test

المؤلفون: Samy Ammari, Salima Hibat-Allah, Frédéric Dhermain, Mathieu Texier, Charlée Nardin, Caroline Robert, Christine Mateus, Emilie Lanoy

المصدر: Melanoma research. 28(2)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, Population, Ipilimumab, Dermatology, Pembrolizumab, Antibodies, Monoclonal, Humanized, Radiosurgery, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Internal medicine, parasitic diseases, Clinical endpoint, Medicine, Humans, Neoplasm Metastasis, Prospective cohort study, education, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Brain Neoplasms, Melanoma, Chemoradiotherapy, Middle Aged, medicine.disease, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Nivolumab, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf47e8d5161bd7b7d968441998e4af3eTest
https://pubmed.ncbi.nlm.nih.gov/29356789Test

المؤلفون: Piotr Rutkowski, Alexander C.J. van Akkooi, Michele Maio, Alfonsus J. M. van den Eertwegh, Christian U. Blank, Nageatte Ibrahim, Adnan Khattak, Paolo A. Ascierto, Rahima Jamal, Ralf Gutzmer, Andrew Haydon, Mikhail Lichinitser, Susana Puig, Victoria Atkinson, Mario Mandalà, Sandrine Marreaud, Caroline Robert, Jean-Jacques Grob, Alexander M.M. Eggermont, Stefan Suciu, Stéphane Dalle, Rutger H. T. Koornstra, Leonel Hernandez-Aya, Shahneen Sandhu, Paul Lorigan, Georgina V. Long, Matteo S. Carlino, James Larkin, Dirk Schadendorf

المساهمون: Universitat de Barcelona, Medical oncology, CCA - Cancer Treatment and quality of life

المصدر: Recercat. Dipósit de la Recerca de Catalunya
instname
The New England Journal of Medicine, 378, 1789-1801
New England Journal of Medicine, 378(19), 1789-1801. Massachussetts Medical Society
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Maio, M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P, Ibrahim, N, Marreaud, S, van Akkooi, A C J, Suciu, S & Robert, C 2018, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma ', New England Journal of Medicine, vol. 378, no. 19, pp. 1789-1801 . https://doi.org/10.1056/NEJMoa1802357Test
Dipòsit Digital de la UB
Universidad de Barcelona
The New England Journal of Medicine, 378, 19, pp. 1789-1801

مصطلحات موضوعية: 0301 basic medicine, Male, Skin Neoplasms, Medizin, Pembrolizumab, Kaplan-Meier Estimate, Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Disease-Free Survival, Double-Blind Method, Female, Humans, Infusions, Intravenous, Intention to Treat Analysis, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Survival Rate, Gastroenterology, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Immunologic, Monoclonal, 80 and over, Humanized, Adjuvant treatment of cancer, education.field_of_study, General Medicine, Local, 030220 oncology & carcinogenesis, Intravenous, medicine.drug, Tractament adjuvant del càncer, medicine.medical_specialty, Infusions, Population, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, Adjuvants, education, Survival rate, business.industry, Cancer, medicine.disease, 030104 developmental biology, Neoplasm Recurrence, Cutaneous melanoma, business, Placebos (Medicine)

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ae9f22b7acc35569131373f281fa946Test
https://doi.org/10.1056/NEJMoa1802357Test

المؤلفون: Caroline Robert, Michele Maio, Alexander M.M. Eggermont

المصدر: Seminars in Oncology. 42:429-435

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, Population, Antineoplastic Agents, Ipilimumab, Pembrolizumab, Cancer Vaccines, Internal medicine, medicine, Humans, Immunologic Factors, education, Melanoma, education.field_of_study, business.industry, Cancer, Hematology, Immunotherapy, medicine.disease, Immunology, Tumor Escape, Nivolumab, business, Adjuvant, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f717f99bf6744c7bd5e6f62494658eeTest
https://doi.org/10.1053/j.seminoncol.2015.02.010Test

المؤلفون: Christian U. Blank, Antoni Ribas, Ana Arance, Scot Ebbinghaus, Honghong Zhou, James Larkin, Jean-Jacques Grob, Jacob Schachter, Matteo S. Carlino, Laurent Mortier, Adil Daud, Omid Hamid, Michal Lotem, Paul Lorigan, Catriona M. McNeil, Bart Neyns, Teresa M. Petrella, Georgina V. Long, Nageatte Ibrahim, Caroline Robert

المساهمون: Laboratory of Molecullar and Cellular Therapy, Laboratory for Medical and Molecular Oncology, Clinical sciences, Medical Oncology

المصدر: Lancet (London, England). 390(10105)

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Skin Neoplasms, Adolescent, Population, Phases of clinical research, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Endocrine System Diseases, Drug Administration Schedule, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Antineoplastic Agents, Immunological, Internal medicine, Journal Article, Medicine, Humans, education, Melanoma, Aged, Aged, 80 and over, education.field_of_study, Performance status, business.industry, Hazard ratio, General Medicine, Middle Aged, Colitis, Surgery, Regimen, 030104 developmental biology, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Female, Chemical and Drug Induced Liver Injury, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0b1b2d09def6d265b755196bc36b1baTest
https://pubmed.ncbi.nlm.nih.gov/28822577Test

المؤلفون: Alexander M.M. Eggermont, Dirk Schadendorf, Caroline Robert

المصدر: Melanoma Development ISBN: 9783319413174

مصطلحات موضوعية: Oncology, education.field_of_study, medicine.medical_specialty, business.industry, medicine.medical_treatment, Melanoma, Population, Medizin, Ipilimumab, Pembrolizumab, Immunotherapy, medicine.disease, Internal medicine, Immunology, medicine, Stage (cooking), Nivolumab, education, business, Adjuvant, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::249991cb63724e7b34dd1a7ed0d234f8Test
https://doi.org/10.1007/978-3-319-41319-8_17Test

المؤلفون: Christian U. Blank, Adil Daud, Rene Gonzalez, Kim Margolin, Scot Ebbinghaus, Ziwen Wei, Dirk Schadendorf, Antoni Ribas, Anna C. Pavlick, Lee D. Cranmer, Caroline Robert, April K.S. Salama, Jacob Schachter, Omid Hamid, Reinhard Dummer, Nageatte Ibrahim, F. Stephen Hodi, Igor Puzanov, Tara C. Gangadhar, Paolo A. Ascierto

المساهمون: University of Zurich, Hamid, Omid

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Phases of clinical research, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, 1306 Cancer Research, Melanoma, Aged, 80 and over, education.field_of_study, Cross-Over Studies, Drug Substitution, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Population, Ipilimumab, 610 Medicine & health, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, education, Protein Kinase Inhibitors, Aged, Chemotherapy, business.industry, medicine.disease, Confidence interval, Surgery, 030104 developmental biology, Drug Resistance, Neoplasm, Mutation, business

وصف الملف: 721_Hamid_O._et_al._Final_analysis_of_randomised_trial_comparing_pembrolizumab_versus_Eur_J_Cancer_2017.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab24a3779538f584d0432f320113cbb5Test
https://www.ncbi.nlm.nih.gov/pubmed/28961465Test